Events and quotes from media sources around the world on research and technologies related to Diamyd Medical.
Information presented here are not press releases and may include excerpts from and links to externally published content.
Diamyd Medical is not responsible for externally published content.
Sort order 
 February 16, 2017   United Kingdom Pilot study shows stable insulin production in type 1 diabetes
A small pilot study in which researchers attempted to slow attacks mounted by the immune system on insulin-producing cells in type 1 diabetes has given promising results.

In the study reported here, DIAGNODE, researchers from Linköping University have injected GAD-alum directly into lymph nodes in the groin, rather than under the skin, in order to determine whether this causes the immune response to become more tolerant towards the body's own GAD protein.

Six patients aged 20-22 years who had been diagnosed with type 1 diabetes up to 6 months previously were included in the study.

The study by researchers at Linköping University in Sweden has been published in the scientific journal New England Journal of Medicine.

"If these results are confirmed when we test more patients, it would be an extremely important advance. The way in which type 1 diabetes progresses differs between individuals for many reasons, and this means that it is not necessary to find a treatment that has excellent effects for everyone. Even if it helps only half of patients, this would be a major step forward," says Johnny Ludvigsson.

Read full article here
 February 16, 2017   Sweden Pilotstudie visar lovande resultat för diabetes typ 1

Vid diabetes typ 1 är det kroppens eget immunförsvar som attackerar de insulinproducerande cellerna. Forskningen kring diabetes typ 1 kretsar därför kring att hitta fungerande antikroppar mot kroppens egna betaceller. Ett sådant protein är GAD65, som forskargrupper i Sverige under lång tid försökt utveckla till att bli ett fungerande läkemedel vid diabetes typ 1.

– Det är första gången överhuvudtaget som ett autoantigen sprutats in i en lymfkörtel i behandling av en autoimmun sjukdom, och givetvis något helt nytt vid diabetes typ 1, säger Johnny Ludvigsson, professor vid Linköpings universitet och huvudledare av studien.

I pilotstudien, som publiceras i New England Journal of Medicine, har sex patienter mellan 20 och 22 år som alla nyligen fått diagnosen diabetes typ 1, ingått.

Läs hela artikeln här